Summary
• Shattuck Labs, Inc. shares increased 16.2% to $2.44 during intraday trading without a clear catalyst.
• The stock’s rise follows the announcement of participation in investor conferences in December, aimed at showcasing innovative therapies.
• Year-to-date performance shows a 63.6% increase, with a quarterly spike of 167.9%, despite a monthly decline of 10%.
Shares of Shattuck Labs, Inc. soared to $2.44 during intraday trading, marking a 16.2% increase from an undisclosed previous close. The stock’s notable price action comes amid routine trading without a defined catalyst.
Investor Conference Participation Sparks Interest
The recent surge in Shattuck Labs’ stock is likely linked to the announcement made on November 20, 2025, regarding the company’s participation in multiple investor conferences throughout December. The management will present at the Piper Sandler 37th Annual Healthcare Conference and engage in one-on-one meetings, led by Taylor Schreiber, M.D. This event provides a platform for the company to showcase its innovative therapies targeting tumor necrosis factor superfamily receptors, crucial for treating inflammatory and immune-mediated diseases.
Recent Performance Overview
Investors may also take note of Shattuck Labs’ performance metrics. The company has shown a year-to-date performance increase of 63.6%. Additionally, the stock has seen a quarterly performance spike of 167.9%, reflecting significant upward momentum in recent months. Despite a decline in monthly performance of 10%, the annual increase of approximately 70.7% underscores its strong recovery over the year.
Market and Technical Picture
The technical indicators for STTK suggest a relatively stable trading environment. The 14-day Relative Strength Index (RSI) stands at 56.2, indicating the stock is neither overbought nor oversold. The average volume over the past 10 days is roughly 101,237 compared to the three-month average of 626,697, suggesting heightened interest but still below typical trading levels.
Analyst Sentiment
Shattuck Labs carries a “Buy” analyst rating, aligning with the stock’s recent upward trajectory. While specific analyst surprises were noted in previous quarters, there are no new ratings or revisions in the last 24 hours.